Pathology & Oncology Research

, Volume 13, Issue 3, pp 243–247

Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome

Authors

  • Anita Maász
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • Péter Kisfali
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • Katalin Horvatovich
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • Márion Mohás
    • 2nd Department of Medicine and Nephrological CenterUniversity of Pécs
  • Lajos Markó
    • 2nd Department of Medicine and Nephrological CenterUniversity of Pécs
  • Veronika Csöngei
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • Bernadett Faragó
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • Luca Járomi
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • Lili Magyari
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • Enikő Sáfrány
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • Csilla Sipeky
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
  • István Wittmann
    • 2nd Department of Medicine and Nephrological CenterUniversity of Pécs
    • Department of Medical Genetics and Child DevelopmentUniversity of Pécs
Article

DOI: 10.1007/BF02893505

Cite this article as:
Maász, A., Kisfali, P., Horvatovich, K. et al. Pathol. Oncol. Res. (2007) 13: 243. doi:10.1007/BF02893505

Abstract

The −1131C is a naturally occurring variant of the apolipoprotein A5 (ApoA5) gene, which has been shown to associate with increased triglyceride levels. This variant has also been shown to confer risk for development of ischemic heart disease and stroke. The gene is in linkage disequilibrium with factors known to correlate with impaired glucose homeostasis. These observations prompted us to study the prevalence of the ApoA5 –1131C allele in patients with metabolic syndrome. A total of 201 metabolic syndrome patients and 210 controls were studied. In both groups the triglyceride levels of patients with −1131C allele were significantly increased compared to the subjects with −1131T allele (3.22 ±0.43 mmol/1 vs. 2.24 ±0.12 mmol/1, p<0.01 in the metabolic syndrome patients; 2.10 ±0.19 mmol/1 vs. 1.22 ±0.05 mmol/1, p<0.01 in the controls). In metabolic syndrome patients the prevalence of the ApoA5 –1131C variant was increased compared to the healthy controls (11% vs. 6.20%). Multiplex regression analysis model adjusted for age, gender, serum total cholesterol levels, acute myocardial infarction and stroke events revealed that the examined ApoA5 variant confers risk for the development of metabolic syndrome: the odds ratio at 95% confidence interval was 3.622 (1.200–10.936), p=0.02. Our findings strongly suggest that this variant is a risk factor for the development of hypertriglyceridemia and metabolic syndrome.

Key words

metabolic syndromeglucose intoleranceApoA5T-1131C

Copyright information

© Arányi Lajos Foundation 2007